CN108815175A - A kind of spray that eye is applied outside - Google Patents
A kind of spray that eye is applied outside Download PDFInfo
- Publication number
- CN108815175A CN108815175A CN201810390024.0A CN201810390024A CN108815175A CN 108815175 A CN108815175 A CN 108815175A CN 201810390024 A CN201810390024 A CN 201810390024A CN 108815175 A CN108815175 A CN 108815175A
- Authority
- CN
- China
- Prior art keywords
- eye
- content
- spray
- spray outside
- applying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides and applies spray outside a kind of eye containing phosphatide and glycine betaine, and wherein content of phospholipid is 1-100mg/ml, beet alkali content 1-100mg/ml；Preferably, content of phospholipid 1-20mg/ml, beet alkali content 1-50mg/ml；Further preferably, content of phospholipid 5-15mg/ml, beet alkali content 10-30mg/ml.Spray is applied outside eye provided by the invention, eye part skin barrier can not only be penetrated, xerophthalmia is safely and effectively treated, and be able to extend the time of action, improve the comfort level of patient.Also, spray is applied outside eye of the invention as the carrier with pharmacology or beautifying active substance, the permeable membrane uptake of active material is can be improved, improves bioavilability, while irritation is not generated to eye.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, and in particular to a kind of spray that eye is applied outside.
Background technique
Xerophthalmia is a kind of common ophthalmology disease, is that lacrimal secretion is caused to reduce or evaporate too strong, tear by many reasons
Membrane stability reduces, and then the general name for one group of disease for causing ocular surface injury to be characterized.The common sympton of xerophthalmia is eye part
Stimulation, photophobia, pain, eye-blurred, fatiguability etc..If xerophthalmia cannot be treated effectively, cornea, conjunctiva may be will form
Keratinization, ulcer, so as to cause eyesight degradation.As video display terminal such as computer, TV and mobile phone etc. are in people
Extensive infiltration and contact lens in life are widely used, since frequency of twinkling for a long time reduces, the exposure of ocular tissue
Increase etc. causes xerophthalmia crowd more and more.It is mainly at present artificial tears for the treatment of xerophthalmia and various types of
Eyedrops.No matter artificial tears or eyedrops require directly to instill when in use intraocular, and the compliance of patient is poor.
Patent CN1456167A provides a kind of artificial tears containing phosphatide, and patent CN1634123A provides one kind and contains
There is the ophthalmic drug delivery system of phosphatide and sodium hyaluronate, patent CN1651090A provides a kind of eye containing trehalose and Hyaluronic Acid
Portion's medication transmission system.The above-mentioned ophthalmic remedy mentioned in the prior art is that direct instill intraocularly uses, for the patient
Compliance is poor.It is domestic at present only to instill the preparation intraocularly used for xerophthalmia.
In order to improve the compliance of patient, Britain Reckitt Benckiser has listed a company a kind of ophthalmically acceptable spraying, commodity
Entitled Optrex, main component include soybean lecithin, VitAVitE, this by spraying can be by way of applying outside eye
Alleviate xerophthalmia.But due to the barrier action of skin, the use feeling of patient shorter for the alleviation duration of xerophthalmia
By bad.
Spray belongs to the higher dosage form of safety of current skin or mucosal drug delivery, using also more convenient.But it sprays
Mist agent mainly has there is also some disadvantages：1) due to the barrier action of skin, spray is only applicable to that dosage is small, pharmacological action
Strong drug；2) to skin irritant and anaphylaxis；3) metabolism of skin and storage cavern act on.Skin and mucous layer are human bodies
To a kind of barrier of drug absorption, amphipathic poor or big molecular weight drug is difficult to enter deep layer through skin and mucous membrane tissue
Tissue and blood circulation play therapeutic effect.Drug is promoted to penetrate skin at present, the method for mucous membrane relies primarily on chemical absorbing rush
Increase the absorption of drug into agent.Although these chemical promoters can improve drug penetrance, most to chemically assist in
Agent can be damaged or be stimulated to skin, mucous membrane.
In order to overcome the drawbacks of the prior art, it is desirable to provide a kind of spray that eye is applied outside can not only penetrate eye
Skin barrier safely and effectively treats xerophthalmia, and is able to extend the time of action, improves the comfort level of patient.It is unexpected
, application spray can be improved active material as the carrier with pharmacology or beautifying active substance to eye of the invention outside
Permeable membrane uptake, improve bioavilability, while irritation do not generated to eye.
Summary of the invention
The present invention provides a kind of spray that eye is applied outside, can treat xerophthalmia through skin barrier, can obviously prolong
Long onset time substantially increases the level of comfort of user, and can be as the load with pharmacology or beautifying active substance
Body promotes the absorption of active material, improves its bioavilability.
To achieve the goals above, technical scheme is as follows：
The present invention provides and applies spray outside a kind of eye, includes phosphatide and glycine betaine.
It is applied in spray outside above-mentioned eye, also comprising conventional eye-drops preparations auxiliary material and purified water.
It is applied in spray outside above-mentioned eye, content of phospholipid 1-100mg/ml, beet alkali content 1-100mg/ml.
It is applied in spray outside above-mentioned eye, content of phospholipid 1-20mg/ml, beet alkali content 1-50mg/ml.
It is applied in spray outside above-mentioned eye, content of phospholipid 5-15mg/ml, beet alkali content 10-30mg/ml.
It is applied in spray outside above-mentioned eye, also includes volatile solvent, be selected from ethyl alcohol, volatile silicone oils.
It is applied in spray outside above-mentioned eye, also includes preservative, prick chlorine peace, Phenoxyethanol, oxybenzene selected from benzalkonium bromide, benzene
Methyl esters, ethyl hydroxy benzoate, butyl hydroxybenzoate, Nipasol, Phenoxyethanol, Butylated Hydroxytoluene, sodium benzoate, potassium sorbate, benzoic acid, chlorine
The sweet ether of benzene, EDTA.
It is applied in spray outside above-mentioned eye, also includes moisturizer, be selected from serine, Sodium Hyaluronate, propylene glycol, fourth two
Alcohol, glycerol, dipropylene glycol, acetylation Sodium Hyaluronate, carambola leaf extract, 1,2- pentanediol, panthenol, trehalose.
It is applied in spray outside above-mentioned eye, also includes antioxidant, be selected from vitamin E adenosine, retinol, tocopheryl acetate
Ester, tocopheryl nicotinate, Matrixyl -4, glutathione, aspartic acid.
It applies in spray outside above-mentioned eye, also includes pH adjusting agent, it is slow to, carbonic acid to, borate buffer selected from phosphoric acid buffer
Punching to, hydrochloric acid, sodium hydroxide, sodium citrate, potassium hydroxide, tromethamine.
It is applied in spray outside above-mentioned eye, also includes isotonic regulator, selected from sodium chloride, mannitol, glucose etc..
It is applied in spray outside above-mentioned eye, also includes natural extracts, extracted selected from ginkgo biloba extract, banaba
Object, ginseng root extract, retinyl acetate, Rosmarinus officinalis extract, safflower extract, Portugal leaf extract, Abelmoschus esculentus fruit
Extract, oriental cherry leaf extract, Rosa roxburghii Tratt berry extract, houttuynia extract, Wild soybean seed extract, Fructus Hordei Vulgaris extract, wheat
Germ extracts, yeast extract, radix scutellariae root extract, chicken mulberry root extract, lactobacillus fermentation product, algae extract, Fu
Siberian cocklebur sclerotium extract, Echinacea angustifolia extract, Roman chamomile caul-fat, it is phytosphingosine, Japanese birch bark/leaf extract, big
Any of several broadleaf plants berry extract, oat extract, silk tree bark extract, lemon thyme flower/leaf extract.
The present invention provides the preparation method that spray is applied outside a kind of above-mentioned eye, comprises the steps of：
(1) glycine betaine is added in purified water, high speed shear；
(2) phosphatide is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Spray is applied outside above-mentioned eye can be used as carrier addition pharmacological activity or cosmetic active agent.
Signified glycine betaine of the invention refers to that the glycine betaine in any source, including animal vegetable tissue extraction are isolated, are micro-
What biofermentation or genetic engineering were prepared etc..
Signified phosphatide of the invention refers to the phosphatide in any source, including the phosphatide extracted in yolk or soybean, and with
The phosphatide that synthesis or semisynthesis obtain, or a combination thereof.
Specific embodiment
Comparative example 1
Preparation method：
(1) Sodium Hyaluronate, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Comparative example 2
Preparation method：
(1) chloramphenicol, Sodium Hyaluronate, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Comparative example 3
Optrex is ophthalmically acceptable spraying, and every 1ml includes soybean lecithin 10mg, VITAMIN A PALMITATE 0.25mg, vitamin
E0.02mg, Phenoxyethanol 5mg, ethyl alcohol 8mg, sodium chloride 8mg, remaining is purified water.
Embodiment 1
Preparation method：
(1) glycine betaine, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Embodiment 2
Preparation method：
(1) glycine betaine, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Embodiment 3
Preparation method：
(1) glycine betaine, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Embodiment 4
Preparation method：
(1) glycine betaine, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Embodiment 5
Preparation method：
(1) glycine betaine, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Embodiment 6
Preparation method：
(1) chloramphenicol, glycine betaine, sodium chloride are added in purified water, high speed shear；
(2) egg yolk lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
Embodiment 7
Preparation method：
(1) glycine betaine, sodium chloride, ethyl alcohol, Phenoxyethanol are added in purified water, high speed shear；
(2) soybean lecithin is added while step (1) high speed shear；
(3) it homogenizes mixture is high-pressure homogeneous obtained by step (2)；
(4) it filters, it is filling.
1 rabbit xerophthalmia model testing experiment of test case
Experimental animal and material healthy rabbits 56, weight 2.5-3.0kg, age 4-5 month.Surgical removal rabbit right eye tear
After gland, Harder gland and instant embrane, is smeared with 50% trichloroacetic acid away from bulbar conjunctiva other than corneal limbus 3mm, rabbit dry eye model, art is made
Start to observe within the 3rd week afterwards.56 rabbit are randomly divided into 7 groups, every group 8.
Administration：One group is control group, gives the blank spray containing only sodium chloride, ethyl alcohol and purified water, remaining six groups of examination
Test group give respectively comparative example 1, embodiment 1-5 eye outside apply spray.Every rabbit right eye is given 3 times daily, two spray every time,
It is used in conjunction 10 days, the 1 right eye angle conjunctiva Schirmer I of inspection in every two days tested wet length and Rose bengal stain situation, according to treatment 10 days
Data evaluation curative effect afterwards.
As a result shown in following Tables 1 and 2：
1 different times Schirmer I of table tests wet long relatively
The average tiger of 2 different times angle conjunctiva of table it is red points compare
According to above-mentioned experimental result it can be found that the embodiment of the present invention 1 (phosphatide+glycine betaine) and (phosphatide+sea of comparative example 1
Algae sugar) comparison it can be found that being applied outside eye of the invention spraying more preferable for the therapeutic effect of xerophthalmia.According to embodiment 1-
5 data are it can be found that apply spraying fine to xerophthalmia curative effect, and the effect of embodiment 2 and 3 outside eye prepared by the present invention
Fruit is more excellent.
2 permeable membrane aptitude tests of test case test
It is saturating that application spray outside the eye containing chloramphenicol obtained by embodiment 6 and comparative example 2 is measured using chicken element cyst membrane
Cross the ability of biomembrane.
The processing of chicken element cyst membrane：New freshly-slaughtered poultry element capsule is taken, is cleaned, fat deposit is removed, is soaked in spare in physiological saline.
Through biofilm experiments：Using Transdermal diffusion cell, chicken element cyst membrane is taken to be cut into suitable size, be fixed on supply chamber with
Between receiving chamber, saline injection makes probe tube liquid level be slightly above film in receiving chamber, records the liquid measure of addition.Open magnetic force
Blender and constant temperature oil bath, keep constant speed stirring, and 37 DEG C of constant temperature spray 200 μ L spray solutions in the chicken element cyst membrane face of supply chamber
On, in 5min, 10min, 30min draws receiving chamber solution 1ml from sample tap and is measured, and supplements fresh life in receiving chamber
Salt water 1ml is managed, acquired sample will be measured three times using Syrups by HPLC drug transmitance.Performance liquid chromatographic column：With
Octadecylsilane chemically bonded silica is filler；Mobile phase A is that 0.01mol/L sodium heptanesulfonate buffer solution (takes biphosphate
Potassium 6.8g dissolves and is diluted to 1000ml with 0.01mol/L heptanesulfonic acid ammonium salt solution, then plus triethylamine 5ml, mix, use phosphoric acid
PH value is adjusted to 2.5), Mobile phase B is methanol；Detection wavelength is 277nm, and according to the form below carries out linear gradient elution.Sampling volume：
10μl。
Test result is as shown in table 3 below：
3 permeable membrane aptitude tests result of table
| 10min permeable membrane rate/% | |
| Comparative example 1 | 37.5 |
| Embodiment 6 | 77.2 |
According to the above results it can be found that chloramphenicol eye external spraying agent prepared by the embodiment of the present invention 6 penetrates biomembrane
Ability is significantly relatively strong, and transmitance is greater than 75% in 10min, facilitates drug and quickly enters eye performance curative effect.
3 bioavailability study of test case
Use the eye external spraying agent containing chloramphenicol of comparative example 2 and embodiment 6, every time two spray.It is delivered referring to Nie's achievement etc.
Document《HPLC method measures mass concentration of the chloramphenicol ophthalmic solution in rabbit aqueous humor》In detection method, investigate it in rabbit eyes
Bioavilability in aqueous humor, as a result see the table below 4.
Pharmacokinetic parameter in 4 rabbit aqueous humor of table
| Group | Cmax(μg/ml) | AUC(min·μg/ml) |
| Comparative example 2 | 0.13 | 10.42 |
| Embodiment 6 | 0.35 | 26.11 |
According to the above results it can be found that the eye external spraying agent prepared by the present invention containing chloramphenicol, has higher biology
Availability.
The action perdurabgility research of test case 4
Experimental animal and material healthy rabbits 18, weight 2.5-3.0kg, age 4-5 month.Surgical removal rabbit right eye tear
After gland, Harder gland and instant embrane, is smeared with 50% trichloroacetic acid away from bulbar conjunctiva other than corneal limbus 3mm, rabbit dry eye model, art is made
Start to observe within the 3rd week afterwards.18 rabbit are randomly divided into 3 groups, every group 6.
Administration：One group is control group, gives the blank spray containing only sodium chloride and purified water, remaining two groups of test component
The spray of comparative example 3, embodiment 7 is not given.After every rabbit right eye gives two sprays, right eye is checked in 0.5h, 1h, 2h, 3h, 4h
Cornea Schirmer I tests wet length (data that every rabbit measures before administration are 0h data), log.
According to listing test result it can be found that the ophthalmically acceptable of the embodiment of the present invention 7 by spraying can hold the alleviation of xerophthalmia
Continue to 4h, and the ophthalmically acceptable of comparative example 3 is only capable of the alleviation of xerophthalmia to continue 2h by spraying.
Embodiment 8
Embodiment 9
Using spray is applied outside eye prepared by embodiment 8-9, can effectively treat xerophthalmia, and be added pharmacology or
It can be improved permeability and bioavilability when beautifying active substance.
Above content describes the prefered embodiments of the present invention in detail.But the present invention is not limited to above-mentioned embodiment party
Detail in formula can carry out a variety of simple changes to technical solution of the present invention within the scope of the technical concept of the present invention
Type, these simple variants all belong to the scope of protection of the present invention.
It is further to note that specific technical features described in the above specific embodiments, in not lance
In the case where shield, it can be combined in any manner.In order to avoid unnecessary repetition, the present invention is to various possible groups
No further explanation will be given for conjunction mode.
In addition, various embodiments of the present invention can be combined randomly, without departing from this hair
Bright thought, it should also be regarded as the disclosure of the present invention.
Claims (10)
1. applying spray outside a kind of eye, which is characterized in that include phosphatide and glycine betaine.
2. applying spray outside eye according to claim 1, which is characterized in that also comprising conventional eye-drops preparations auxiliary material and pure
Change water.
3. applying spray outside eye according to claim 1, which is characterized in that the content of phospholipid is 1-100mg/
Ml, beet alkali content 1-100mg/ml.
4. applying spray outside eye according to claim 3, which is characterized in that the content of phospholipid is 1-20mg/ml,
Beet alkali content is 1-50mg/ml.
5. applying spray outside eye according to claim 4, which is characterized in that the content of phospholipid is 5-15mg/ml,
Beet alkali content is 10-30mg/ml.
6. applying spray outside eye according to claim 1, which is characterized in that also include preservative, selected from benzalkonium bromide,
Benzene pricks chlorine peace, Phenoxyethanol, methyl hydroxybenzoate, ethyl hydroxy benzoate, butyl hydroxybenzoate, Nipasol, Phenoxyethanol, Butylated Hydroxytoluene, benzene first
Sour sodium, potassium sorbate, benzoic acid, Chlorphenesin, EDTA.
7. applying spray outside eye according to claim 1, which is characterized in that also include antioxidant, be selected from vitamin E gland
Glycosides, retinol, tocopherol acetate, tocopheryl nicotinate, Matrixyl -4, glutathione, aspartic acid.
8. applying spray outside eye according to claim 1, which is characterized in that it also include pH adjusting agent, it is slow selected from phosphoric acid
Punching to, borate buffer to, carbonic acid buffering to, hydrochloric acid, sodium hydroxide, sodium citrate, potassium hydroxide, tromethamine.
9. applying the preparation method of spray outside -8 any eyes according to claim 1, comprise the steps of：
（1）Glycine betaine is added in purified water, high speed shear；
（2）In step（1）Phosphatide is added while high speed shear；
（3）By step（2）Gained mixture is high-pressure homogeneous to be homogenized；
（4）Filtering, it is filling.
10. spray is applied outside eye described in -9 according to claim 1, which is characterized in that applying spray outside the eye can
Pharmacological activity or cosmetic active agent is added as carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810390024.0A CN108815175A (en) | 2018-04-26 | 2018-04-26 | A kind of spray that eye is applied outside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810390024.0A CN108815175A (en) | 2018-04-26 | 2018-04-26 | A kind of spray that eye is applied outside |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108815175A true CN108815175A (en) | 2018-11-16 |
Family
ID=64155730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810390024.0A Withdrawn CN108815175A (en) | 2018-04-26 | 2018-04-26 | A kind of spray that eye is applied outside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815175A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111728913A (en) * | 2020-07-23 | 2020-10-02 | 广州柏俐臣化妆品有限公司 | Polypeptide acne-removing composition and preparation method and application thereof |
| CN113876807A (en) * | 2021-10-18 | 2022-01-04 | 物生生物科技(北京)有限公司 | Spray composition for treating eye diseases and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1456167A (en) * | 2003-03-31 | 2003-11-19 | 凌沛学 | Artificial tear containing phosphatide and preparing method thereof |
| CN102512420A (en) * | 2011-11-29 | 2012-06-27 | 北京阜康仁生物制药科技有限公司 | Officinal composite using Rebamipide officinal salt as active ingredient |
| CN108567737A (en) * | 2017-03-10 | 2018-09-25 | 深圳君圣泰生物技术有限公司 | Liquid composition and its use device |
-
2018
- 2018-04-26 CN CN201810390024.0A patent/CN108815175A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1456167A (en) * | 2003-03-31 | 2003-11-19 | 凌沛学 | Artificial tear containing phosphatide and preparing method thereof |
| CN102512420A (en) * | 2011-11-29 | 2012-06-27 | 北京阜康仁生物制药科技有限公司 | Officinal composite using Rebamipide officinal salt as active ingredient |
| CN108567737A (en) * | 2017-03-10 | 2018-09-25 | 深圳君圣泰生物技术有限公司 | Liquid composition and its use device |
Non-Patent Citations (1)
| Title |
|---|
| 张昕: "渗透压保护剂对ICES小鼠干眼模型的预防和治疗作用", 《万方数据》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111728913A (en) * | 2020-07-23 | 2020-10-02 | 广州柏俐臣化妆品有限公司 | Polypeptide acne-removing composition and preparation method and application thereof |
| CN113876807A (en) * | 2021-10-18 | 2022-01-04 | 物生生物科技(北京)有限公司 | Spray composition for treating eye diseases and application thereof |
| CN113876807B (en) * | 2021-10-18 | 2023-10-27 | 物生生物科技(北京)有限公司 | Spray composition for treating eye diseases and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210220272A1 (en) | Biphasix cannabinoid delivery | |
| CN108498382A (en) | A kind of moisturizing conveys nano-composition and its preparation method and application altogether | |
| US8802085B2 (en) | Compositions for topical treatment of medical conditions including wounds and inflammation | |
| AU2012275113A1 (en) | Alcaftadine for use in the treatment of urticaria | |
| CN111936126A (en) | Cannabinoid dosing regimens for dermatitis and inflammatory skin disorders | |
| KR102475897B1 (en) | Mask cosmetic composition comprising Graviola antibiotic extract and method of preparing the same | |
| EP2763686A1 (en) | Composition for the treatment of skin lesions | |
| CN108125996A (en) | It is a kind of for visual fatigue, dry eyes eye-drops preparations | |
| CN108815175A (en) | A kind of spray that eye is applied outside | |
| CN108542883A (en) | A kind of spray that eye is applied outside | |
| JP7175038B2 (en) | Isotretinoin formulations and uses and methods thereof | |
| CN110787082A (en) | Eye cell repair composition and eye care product containing same | |
| CN111939229A (en) | Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof | |
| JP2010526135A (en) | Use of slimming rare earth elements | |
| US11446277B2 (en) | Penetrating pain relief cream | |
| US20200197379A1 (en) | Composition for preventing or treating atopic dermatitis | |
| CN110974861B (en) | Blumea balsamifera oil liposome | |
| KR100511944B1 (en) | Cosmetic composition comprising asiaticoside | |
| EP3199163A1 (en) | Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies | |
| KR101446706B1 (en) | Composition for skin rejuvenation comprising FGF | |
| US10933111B2 (en) | Treating dry eye disorders | |
| KR20140068285A (en) | Cosmetic composition for skin whitening comprising Ginseng seeds extract | |
| CN113069373A (en) | Dry eye cream, preparation method and application | |
| CN112190576A (en) | Composition of skin external preparation, skin external preparation and preparation method thereof | |
| KR20050048287A (en) | A cosmetic composition for treating atopian skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181116 |